495 related articles for article (PubMed ID: 31926287)
1. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
2. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
[TBL] [Abstract][Full Text] [Related]
6. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
Punekar YS; Parks D; Joshi M; Kaur S; Evitt L; Chounta V; Radford M; Jha D; Ferrante S; Sharma S; Van Wyk J; de Ruiter A
HIV Med; 2021 Jul; 22(6):423-433. PubMed ID: 33529489
[TBL] [Abstract][Full Text] [Related]
11. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
13. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
14. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
Giacomelli A; Lai A; Franzetti M; Maggiolo F; Di Giambenedetto S; Borghi V; Francisci D; Magnani G; Pecorari M; Monno L; Vicenti I; Lepore L; Lombardi F; Paolucci S; Rusconi S;
Antiviral Res; 2019 Dec; 172():104635. PubMed ID: 31629714
[TBL] [Abstract][Full Text] [Related]
15. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
[TBL] [Abstract][Full Text] [Related]
19. Real world use of dolutegravir two drug regimens.
Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
[TBL] [Abstract][Full Text] [Related]
20. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
